表紙
年間契約型資訊服務

Autoimmune Drug Focus (ADF)

Autoimmune Drug Focus

出版商 Fitch Solutions, Inc. 商品編碼 26341
出版日期 12 Issues/Year 內容資訊 英文 24 Pages
價格
Back to Top
Autoimmune Drug Focus (ADF) Autoimmune Drug Focus
出版日期: 12 Issues/Year 內容資訊: 英文 24 Pages
簡介

全球約有4%的人口苦於自我免疫系統疾病,並且罹患率有上升的傾向。每年花費在探究自我免疫系統疾病病因的研究上就有上百萬美金。

在醫藥品市場上專門提供具有權威情報的市調公司Espicom Business Intelligence(總公司:英國),提供自我免疫系統疾病治療藥市場的最新資訊,並出版綜合報告書"Autoimmune Drug Focus (ADF)"

此報告書針對自我免疫系統疾病治療藥的開發狀況、企業及醫療品概要、預計展開會議的相關訊息、市場相關最新資訊等,進行一連串地探討。

<架構>

  • 糖尿病
  • 發炎性腸道疾病(以大腸克隆病及潰瘍性大腸癌為主)
  • 多發性硬化症
  • 肌肉骨骼疾病(以類風濕性關節炎、狼瘡等為主)
  • 牛皮癬
  • 開發狀況
  • 會議清單

<從第 1 號開始的新聞焦點>

  • Cell Therapeutics 公司認可 DiaKine 公司的 LSF 資料庫(專利與智慧財產)
  • 使用寄生蟲治療大腸克隆病的可能性
  • GW Pharmaceuticals 公司有關 Sativex 申請的更新
  • 有關 Celebrex 心血管安全性的多樣研究結果
  • FDA 許可 Remicade 使用在治療僵直性脊椎炎
  • 從加拿大相關機構取得第 III 期牛皮癬治療藥實驗許可的 Isotechnika 公司
  • 在 MHC 第II級抵抗劑研究上締結合夥關係的 GPC 公司與 Debiopharm 公司
  • 握有自我免疫疾病關鍵的選擇性 Splicing
目錄
Product Code: 1746-1243

BMI View: EU approval puts Cosentyx on course to achieve blockbuster status, with US approval also anticipated early in 2015. Novartis' drug has already shown superiority over its main competition in the lucrative adult plaque psoriasis market. As many as 50% of patients are unhappy with their treatments; if Cosentyx can overcome this hurdle it will emerge as a clear winner.

Table of Contents

  • Novartis In Pole Position With Cosentyx' EU Approval For Plaque Psoriasis Diabetes
  • Agreements
  • Lilly/Adocia To Co-Develop BioChaperone Technology-Based Ultra-Rapid Insulin
  • MannKind Earns Milestone Payment From Sanofi
  • Product Updates
  • Tresiba Gains CHMP Positive Opinion For Expanded Use
  • Additional Patent Protection Underlines Diamyd's Potential
  • R&D
  • Positive Preliminary Results Reported From Biodel's BIOD-531 Phase IIa Study In Diabetes
  • Adocia Begins Phase Ib Trial To Evaluate Post-Meal Effect Of BioChaperone Lispro Inflammatory Bowel Diseases
  • Agreements
  • TxCell/Ferring Collaborate With Trizell For Development Of Ovasave
  • Janssen/Vedanta Sign Licensing Deal For Microbiome Candidate In IBD
  • Product Updates
  • TxCell Secures Funds For Ovasave Development In Refractory Crohn's Disease
  • R&D
  • Galapagos Initiates Phase II Trial Of GLPG1205 In UC
  • Positive Results Reported From Arena's APD334 Phase Ib Trial In Autoimmune Diseases
  • TiGenix Granted European Patent Covering Adipose-Derived Stem Cell Compositions Multiple Sclerosis
  • Product Updates
  • Takeda Submits Glatiramer Acetate NDA In Japan For Relapse Prevention Of MS
  • Supreme Court Ruling Will Boost Teva's Copaxone Revenues
  • R&D
  • First Patient Treated In Mapi's Phase IIa Trial Of GA Depot For RRMS Musculoskeletal Disorders
  • Arthritis - Agreements
  • Torrent And Reliance Life Sciences Enter India Biosimilars Agreement
  • Product Updates
  • Health Canada Approves Actemra For Early RA
  • EMA Accepts Samsung Bioepis' Etanercept Biosimilar For Review
  • R&D
  • NSAID Market Set To Welcome Encapsulated Equivalents
  • Can-Fite Completes Design Of CF101 Phase III RA Study
  • Duvelisib Phase II RA Study Misses Primary Endpoint
  • Other Musculoskeletal Disorders - R&D
  • Premier Files Initial FDA Submission For Fibromyalgia Treatment Psoriasis
  • Product Updates
  • Novartis' Cosentyx Approved In Japan For Psoriasis Vulgaris/PsA
  • LEO Submits NDA For Calcipotriene+Betamethasone Aerosol Foam In Plaque Psoriasis
  • Perrigo Launches Clobetasol Spray In US
  • EU Approval Sets Stage For Otezla's Blockbuster Future
  • Novartis' Cosentyx Gains FDA Approval For Plaque Psoriasis
  • R&D
  • Kadmon Initiates KD025 Phase II Trial In Psoriasis
  • Cimzia Phase III Programme Initiated In Psoriasis General Developments
  • Agreements
  • OrImmune/Nanjing BioSciKin Enter China Anti-CD3 Antibody Collaboration
  • Tiziana Licenses Foralumab From Novimmune
  • EpiVax/Novozymes Enter Tregitope Autoimmune Agreement
  • Isis/Janssen To Co-Develop Antisense Drugs For GI Tract Autoimmune Disorders
  • Evotec/Padlock Extend Collaboration
  • Genomic Data Partnerships Will Bolster Drug Development
  • Product Updates
  • GSK Submits Promacta sNDA To FDA
  • EU Approval For Ofev In IPF Will Create A Blockbuster In An Intense Market
  • R&D
  • ImmuPharma/Simbec-Orion Collaborate To Begin Lupuzor Phase III Study In SLE Corporate Activity
  • Padlock Raises Funds To Advance PAD-Directed Therapeutics
  • Aldeyra Raises Funds Via Private Placement Conference Listings
Back to Top